Company: LGNZZ
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0000886163-25-000025
Chunk: 70

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 70
---
 actually paid to our NEOs for the fiscal year ended December 31, 2024 :

• Revenue

• Adjusted EBITDA

• Total Shareholder Return

The measures in the above list are not ranked. For additional details regarding how we link pay to financial performance measures, please see the section titled “Elements of Compensation—Annual Performance-Based Cash Compensation” and “Elements of Compensation—Long-Term Performance-Based Equity Incentive Program” in our Compensation Discussion and Analysis above.

56

### COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION
During fiscal 2024, the Human Capital Management and Compensation Committee was composed of Mr. Haas, Dr. LaMattina, and Mr. Aryeh. No executive officer of our company served on the board of directors or compensation committee of any entity which has one or more executive officers serving as members of our Board or Human Capital Management and Compensation Committee.

### EQUITY COMPENSATION PLANS
We have two compensation plans approved by our stockholders under which our equity securities are authorized for issuance to employees and directors for goods or services, the 2002 Plan and the Employee Stock Purchase Plan. We also maintain the 2022 Inducement Plan, or the Inducement Plan, which has not been approved by our stockholders.

The following table summarizes information about our equity compensation plans as of December 31, 2024:

|                                                            |     | -a)                                                                                            
 Number of securities to be issued upon exercises of outstanding options, warrants and rights(1 |           |           | (b)                                                                         
 Weighted-average exercise price of outstanding options, warrants and rights |     |        | -c)                                                                                                                  
 Number of securities                                                                                                 
 remaining available for future issuance under equity compensation plans (excluding securities reflected in column(a) |           |
| Equity compensation plans approved by security holders     |     |                                                                                                |           | 2,664,145 |                                                                             |     | $75.14 | 1,441,717(2)                                                                                                         |           |
| Equity compensation plans not approved by security holders |     |                                                                                                |           |   342,535 |                                                                             |     | $69.07 | 0(3)                                                                                                                 |           |
|                                                            |     |                                                                                                | 3,006,680 |           |                                                                             |     | $74.53 |                                                                                                                      | 1,441,717 |

(1) Includes options and RSUs outstanding under the plans, with PSUs included